NanJing Pharmaceutical (SHA:600713) terminated its planned investment in Ningbo Jiangfeng Bio-information Technology, according to a Wednesday disclosure to the Shanghai bourse.
The company and other investors failed to receive confirmation from the target firm regarding the investment, resulting in the termination.